The extracorporeal CO2 removal devices market is anticipated to grow from US$ 99.93 million in 2022 to US$ 170.54 million by 2030; it is estimated to register a CAGR of 6.9% during 2022-2030.
Market growth is attributed to the increasing chronic obstructive pulmonary diseases (COPD) cases and the growing geriatric population. Rising number of product launches and approvals will likely provide growth opportunities for the extracorporeal CO2 removal devices market. However, strict mandates related to extracorporeal CO2 removal devices hinder the growth of the hyperbaric oxygen therapy market.
Extracorporeal CO2 removal devices are an efficient therapy for patients with hypercapnic respiratory failure. They can enable doctors and healthcare professionals to improve lung protective ventilation. Extracorporeal CO2 removal devices can remove enough CO2 to reduce alveolar minute ventilation by 50%, significantly reducing the partial pressure of carbon dioxide (PaCO2). Therefore, various advantages of extracorporeal CO2 removal devices are expected to increase the overall market development.
North America accounted for a major share of the global extracorporeal CO2 removal devices market in 2022. The North America extracorporeal CO2 removal devices market is segmented into the US, Canada, and Mexico. The market growth in this region is driven by improved healthcare infrastructure and high adoption of extracorporeal CO2 removal devices, especially during the COVID-19 pandemic in the US and Canada. Early adoption of new technologies and a large patient pool for ARDS and COPD are expected to accelerate the growth of the market in the region. The increasing incidence of chronic respiratory diseases and preference for safe and rapid minimally invasive ventilators are further expected to accelerate the growth of the extracorporeal CO2 removal devices market during the forecast period.
Rising Numbers of Product Launches and Approvals Fuels the Extracorporeal CO2 Removal Devices Market Growth Opportunities
In recent years, technological improvements and strategies have reduced the complexity and size of extracorporeal CO2 removal devices. A gradual increase in technological advancement has facilitated the growth of security and acceptance of these devices. Various technological advancements have made extracorporeal CO2 removal devices feasible and easy, providing further options to assist patients with severe respiratory diseases and high mortality risk.
- In November 2021, ALung Technologies received FDA de novo clearance for its Hemolung respiratory support system, the first extracorporeal carbon dioxide removal device.
- In November 2020, X-COR Therapeutics closed a financing round of around US$ 2.6 million. The company intends to use these funds to develop its products further, including ECCO2R devices.
- In April 2020, an emergency use authorization (EUA) was received by ALung Technologies from the US Food and Drug Administration for the hemolung respiratory assist system (RAS) to treat COVID-19.
Therefore, such strategic initiatives are expected to boost the market growth of extracorporeal CO2 removal devices.
Product Type-Based Insights
Based on product, the extracorporeal CO2 removal devices market is divided into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger market share in 2022. The consumables segment is anticipated to register a higher CAGR of during 2022-2030. The process of extracorporeal CO2 removal requires a fresh set of consumables for every patient, owing to which there is a high demand for consumables in various COPD and ARDS-related procedures. Thus, the extracorporeal CO2 removal devices market for the consumables segment is expected to continue to grow during the forecast period
Application-Based Insights
The extracorporeal CO2 removal devices market is segmented based on application into acute respiratory distress syndrome, chronic obstructive pulmonary disease, and others. The chronic obstructive pulmonary disease segment held the largest market share in 2022. The acute respiratory distress syndrome segment is anticipated to register the highest CAGR of 7.7% during 2022-2030.
Increasing awareness of ARDS and its early detection has resulted in more patients being diagnosed and treated, resulting in a greater demand for extracorporeal CO2 removal devices tailored for ARDS management. As a result, healthcare providers have become more confident in incorporating extracorporeal CO2 removal devices into their ARDS treatment protocols.
End User-Based Insights
Based on the end user, the extracorporeal CO2 removal devices market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment held the largest extracorporeal CO2 removal devices market share in 2022 and is anticipated to register the highest CAGR during 2022-2030. Hospitals, particularly those with specialized intensive care units (ICUs) and respiratory facilities, are equipped to care for the most seriously ill patients. In addition, hospitals typically have multidisciplinary teams of healthcare professionals, including pulmonologists, critical care physicians, respiratory therapists, and perfusionists, who work together to treat patients with complex respiratory needs. This expertise is essential for the safe and effective use of ECCO2R devices.
Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquiring a new customer base to tap prevailing business opportunities.
- In October 2022, Alung Technologies evaluated the safety and effectiveness of using the Hemolung RAS for low-flow extracorporeal CO2 removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients requiring respiratory support due to acute exacerbations of COPD.
- In March 2022, Respira Labs, a US-based respiratory health technology company, launched Sylvee. This AI-powered wearable lung monitor uses acoustic resonance to assess lung function and identify lung volume fluctuations. It can help detect and treat COPD, asthma, and COVID-19.
- In May 2021, ALung Technologies, Inc. received FDA clearance for its next-generation Hemolung RAS extracorporeal CO2 removal system, designed to provide respiratory support to patients with acute respiratory failure.
- In May 2020, ALung Technologies, Inc. announced the commercial development of the next-generation artificial lung called the Hemolung Respiratory Assist System (RAS).
The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the extracorporeal CO2 removal devices market report.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Extracorporeal CO2 Removal Devices Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
 4.3.1 List of Vendors in the Value Chain
5. Extracorporeal CO2 Removal Devices Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Extracorporeal CO2 Removal Devices Market - Global Market Analysis
6.1 Extracorporeal CO2 Removal Devices - Global Market Overview
6.2 Extracorporeal CO2 Removal Devices - Global Market and Forecast to 2030
7. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Product, 2020-2030
7.1 Overview
7.2 Extracorporeal CO2 Devices
7.3 Consumables
8. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Application, 2020-2030
8.1 Overview
8.2 Chronic Obstructive Pulmonary Disease
8.3 Acute Respiratory Distress Syndrome
8.4 Others
9. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030
9.1 Overview
9.2 Hospitals and Clinics
9.3 Ambulatory Surgical Centers
9.4 Others
10. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis
10.1 North America
 10.1.1 North America Extracorporeal CO2 Removal Devices Market Overview
 10.1.2 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts to 2030
 10.1.3 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Product
 10.1.4 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Application
 10.1.5 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By End User
 10.1.6 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Countries
 10.1.6.1 United States Extracorporeal CO2 Removal Devices Market
 10.1.6.1.1 United States Extracorporeal CO2 Removal Devices Market, by Product
 10.1.6.1.2 United States Extracorporeal CO2 Removal Devices Market, by Application
 10.1.6.1.3 United States Extracorporeal CO2 Removal Devices Market, by End User
 10.1.6.2 Canada Extracorporeal CO2 Removal Devices Market
 10.1.6.2.1 Canada Extracorporeal CO2 Removal Devices Market, by Product
 10.1.6.2.2 Canada Extracorporeal CO2 Removal Devices Market, by Application
 10.1.6.2.3 Canada Extracorporeal CO2 Removal Devices Market, by End User
 10.1.6.3 Mexico Extracorporeal CO2 Removal Devices Market
 10.1.6.3.1 Mexico Extracorporeal CO2 Removal Devices Market, by Product
 10.1.6.3.2 Mexico Extracorporeal CO2 Removal Devices Market, by Application
 10.1.6.3.3 Mexico Extracorporeal CO2 Removal Devices Market, by End User
 Note - Similar analysis would be provided for below mentioned regions/countries
 
10.2 Europe
 10.2.1 Germany
 10.2.2 France
 10.2.3 Italy
 10.2.4 Spain
 10.2.5 United Kingdom
 10.2.6 Rest of Europe
10.3 Asia-Pacific
 10.3.1 Australia
 10.3.2 China
 10.3.3 India
 10.3.4 Japan
 10.3.5 South Korea
 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
 10.4.1 South Africa
 10.4.2 Saudi Arabia
 10.4.3 U.A.E
 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
 10.5.1 Brazil
 10.5.2 Argentina
 10.5.3 Rest of South and Central America
11. Industry Landscape
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. Extracorporeal CO2 Removal Devices Market - Key Company Profiles
13.1 Getinge AB
 13.1.1 Key Facts
 13.1.2 Business Description
 13.1.3 Products and Services
 13.1.4 Financial Overview
 13.1.5 SWOT Analysis
 13.1.6 Key Developments
 Note - Similar information would be provided for below list of companies
 
13.2 ALung Technologies, Inc.
13.3 Xenios AG
13.4 Estor SpA
13.5 Medtronic
13.6 Hemodec
13.7 NovaLung GmbH
13.8 Baxter Healthcare
13.9 Eurosets
13.10 LivaNova
14. Appendix
14.1 Glossary
14.2 About
14.3 Market Intelligence Cloud
LIST OF TABLES
LIST OF FIGURES
The List of Companies - Extracorporeal CO2 Removal Devices Market
Getinge
ALung Technologies, Inc.
Estor
NovaLung GmbH
Hemodec
Baxter Healthcare
Eurosets
LivaNova
Medtronic
Xenios AG